Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after ...

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a heated bidding war with Novo Nordisk A/S for ...

Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the ...

The new offer improves upon Pfizer’s earlier proposal for US$86.20 (RM359.97) a share including milestone payments, said the ...

Pfizer has submitted a sweetened bid for Metsera, an obesity drug developer, as its fight against rival Novo Nordisk ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Democratic Senate Minority Leader Chuck Schumer proposed extending expiring health-care subsidies for one year as part of a measure to reopen the government, in a move aimed at breaking the monthlong ...

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is. | Amid Novo Nordisk and Pfizer’s ...

Eli Lilly and Novo are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs. Blackstone Life Sciences will pay Merck $700 million for ...

The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.